Pharmaceutical Industry News Archive
Get news by email or subscribe to our news feeds.
News Archive for October 2011
October 3, 2011
- MedImmune In-Licenses Cancer Immunotherapy Tremelimumab from Pfizer
- Teva, Medicines Co. Settle Angiomax Patent Lawsuit
- Merck Wins Another Federal Bellwether Trial Regarding FOSAMAX (alendronate sodium)
- SRA Sells Its Global Clinical Development Business
- PPD to be Acquired by The Carlyle Group and Hellman & Friedman
October 4, 2011
- Company Makes Drug Data Accessible
- Merck and Ono Pharmaceutical Form Collaborations to Develop Oral Multiple Sclerosis Drug and Cancer Immunotherapy
- Pharmaceutical Product Development Agrees to Be Bought for $3.9 Billion
- Merck Reports Fourth Win in Fosamax Litigation
- A New Mission for Pfizer
- Ranbaxy to Extend Daiichi Sankyo Product Reach to Pharmacists Across Italy
October 5, 2011
- Labopharm and Angelini Complete the Restructuring of their Partnership
- Merck and Ariad Seek US Approval for Cancer Pill
- Dynavax and AstraZeneca to Advance TLR-9 Agonist Into Clinic for Asthma
- Bayer Plans Continued Growth in Japan
- Brilique Receives A Positive Preliminary Medical Benefit Assessment for the Majority of ACS Patients in Germany As Part of New AMNOG Review Process
- AstraZeneca Enters Into A Settlement Agreement With Accord Healthcare, Inc. and Intas Pharmaceuticals Ltd Regarding US Seroquel XR Patent Litigation
- Celgene Pays Agios $20M to Extend Cancer Drug Pact
- MASSPIRG Testifies on Rx Drug Marketing Bills Urges Committee to Support Bills That Rein in Healthcare Costs
October 6, 2011
- Pfizer Invests in Plant in Saudi Arabia
- Johnson & Johnson Subsidiary Scios Pleads Guilty to Misbranding Heart Failure Drug Natrecor
- New MS Drug Shows Modest Effect on Relapses, Disability in Clinical Trial
- Pfizer Announces Licensing Agreement With Puma Biotechnology, Inc. For The Development And Commercialization Of Neratinib, An Investigational Pan-HER Inhibitor
- Gilead and Boehringer Ingelheim Sign License Agreement for Novel HIV Non-Catalytic Integrase Inhibitors
- Scios Inc. Announces Agreement with Department of Justice Regarding Natrecor
- Michigan House Democrats Demand Action on Drug Industry Immunity Bills
- Pfizer Invests in Plant in Saudi Arabia
- Johnson & Johnson Subsidiary, Scios, Pleads Guilty to Misbranding Heart Failure Drug Natrecor
- Express Scripts Cuts Profit and Prescription Views
- Pfizer Sets Licensing Deal With Puma Biotechnology
- Gilead Sciences Inks Licensing Deal for HIV Drug
- Prescription Sales Through Healthcare Distributors Hit $268 Billion
- Merck Announces Retirement of Chairman and Former CEO Richard T. Clark
October 7, 2011
- AstraZeneca Says 400 Jobs to be Cut
- Takeda Discontinues Development of Ramelteon in Europe for the Treatment of Insomnia
- FDA Approves Additional Use for Lilly's Cialis
- Watson Confirms Embeda Patent Challenge
- FDA Approves First Diabetes-Cholesterol Combo Pill
October 10, 2011
- US FTC Approves Teva's Cephalon Acquisition
- Suit Accuses Pharma Companies of Medicaid Price-data Manipulation
- AstraZeneca Increases Investment in China with New $200 Million Manufacturing Facility
- Victoza Now Available to People with Type 2 Diabetes in China
- Allos Therapeutics Continues to Work Toward Completion of Merger with AMAG Pharmaceuticals
- US Regulators Clear Teva Acquisition of Cephalon
- Pfizer Settles with Teva Over Lipitor in UK
- Watson Provides Update on District Court Order Concerning Generic Version of Lovenox
- Scottish Medicines Consortium Rules Against Breast Cancer Treatment Halaven
- Watson Confirms District Court Order Concerning Generic Version of Lovenox
- Insmed Incorporated Provides Regulatory Update
October 11, 2011
- Isis Selects Development Candidate, Isis-AATRx, to Treat AATD-Associated Liver Disease
- GlycoMimetics and Pfizer Enter into Licensing Agreement for Drug Candidate Currently in Development to Treat Patients Experiencing Vaso-occlusive Crisis Associated with Sickle Cell Disease
- Roche Alzheimer's Drug Reduces Amyloid Levels
- Pharmasset Again Expands Hepatitis C Drug Study
- Lilly Announces Changes in Senior Management
- Brentuximab Vedotin Enters Phase 1/2 Clinical Trial in Japan
- PDL Biopharma Falls After Analyst Cuts Rating
October 12, 2011
- FDA Drug Safety Communication: Sprycel (dasatinib) and Risk of Pulmonary Arterial Hypertension
- Merck Australia Wins Appeal in Vioxx Case
- Pfizer Inks Deals with Firms Working on Sickle Cell and Alzheimer's
- Senate Report: Firms Took Tax Break, Didn't Add Jobs
- Sunesis Pharma Slides Following Analyst Downgrade
- Onyx Pharmaceuticals and Bayer Healthcare Restructure Global Oncology Partnership
- Levin Report Finds Offshore Tax Break Is a Failed Tax Policy Whose Repeat Could Damage the Economy Senate Homeland Security and Governmental Affairs Committee News Release
- Prostate Cancer: Experts Discourage Vitamins and PSA Test
- Oncobiologics Appoints Scott Canute, Former President of Eli Lilly and Genzyme, to its Board of Directors
- Cook Children's Health Care System and athenahealth Announce Nation's First 2D Barcode System for Vaccines
October 13, 2011
- Protesters to Target Pfizer Today
- Fitch Backs Its 'A+' Credit Rating on Merck
- Roche Posts Solid Sales Performance in First Nine Months, Achieves Significant Progress With Personalised Healthcare Approaches
- Jury Awards Couple $104M in Vegas Hepatitis Case
- Roche Blames Franc for 14 Percent Drop in Sales
- Amgen Notifies R&D Staff to Expect Changes
- Teva and Cephalon Receive European Commission Approval For Acquisition
October 14, 2011
- FDA Questions Teva Drug's Impact on Parkinson's
- Insmed Incorporated Provides Regulatory Update on ARIKACE in Non-Tuberculous Mycobacteria Indication
- Protesters Outside Pfizer Campus Criticize Tax Breaks
- Depomed Says Hot Flash Drug Doesn't Meet All Goals
- Mondo Guerra of "Project Runway" Brings National HIV Education Campaign to Philadelphia to Co-Host the Region's Largest HIV/AIDS Public Awareness and Fundraising Event
- Teva Completes Acquisition of Cephalon
- FDA Panel Recommends Cook Medical Stent
- Cephalon Announces Enrollment In the Risk Evaluation and Mitigation Strategy Program for FENTORA and ACTIQ
- Warring Drug Companies Put Profit Above Patients, Claims Author
October 17, 2011
- Group Rejects Skin Cancer Treatment
- Drug Shortages: Companies Pitch Action Plan, Dodge a Health Canada Bullet
- Par Pharmaceutical Files Declaratory Judgment to Protect First Amendment Rights to Disseminate Truthful Information Regarding Megace ES
- Roche Signs Definitive Agreement to Acquire Anadys Pharmaceuticals
- Eisai Enters into Neurological Drug Discovery Research Collaboration with Johns Hopkings University
- Acura to Receive Royalties on Sale of Pfizer Drug
October 18, 2011
- Flamel Technologies Announces Multi-Year Supply Agreement with GlaxoSmithKline for Coreg CR? Microparticles
- Bipartisan Effort to Increase Efficiency at the FDA
- Johnson & Johnson 3Q Profit Down 6 Percent
- Lux Biosciences Gmbh Withdraws Its Marketing Authorisation Application for Luveniq (Voclosporin)
- FDA Panel Unanimously Votes Down Parkinson's Drug
- AstraZeneca and Forest Laboratories to Initiate Phase III Clinical Trials for Ceftazidime/Avibactam to Treat Serious Gram-Negative Bacterial Infections
- Servier and Miragen Sign $352 Million Partnership Agreement for the Research, Development and Commercialization of MicroRNA-targeting Drugs for Cardiovascular Disease
- Teijin Announces Impact of Flooding on Thai Operations
- Takeda Initiates Phase 3 Clinical Trial Program in the United States, Latin America, and Europe for Investigational Type 2 Diabetes Therapy TAK-875
- Forest Laboratories' Net Income Shrinks
October 19, 2011
- Abbott to Separate into Two Leading Companies in Diversified Medical Products and Research-Based Pharmaceuticals
- Abbott Reports Strong Ongoing Third Quarter Results; Confirms Double-Digit Ongoing Earnings Growth Outlook for 2011
- Quintiles Acquires VCG & Associates and VCG Bio
- Human Genome Sciences Rises on Sale Rumors
- Malaria Vaccine Trials Going Well for GSK
- Abbott Labs Plans to Split Into 2 Companies
- Facebook Users With More Friends Also Have Bigger Brains
- Bristol-Myers Squibb Announces Changes in Senior Management Team
October 20, 2011
- More than One-Quarter of U.S. Adults Use their Mobile Phones for Health Information and Tools
- Actelion announces nine months 2011 financial results
- Biogen Idec and Elan Receive Notification of PDUFA Date Extension
- Protox Announces the Dosing of Patients in Transrectal Study
- Lilly Reports Third-Quarter 2011 Results
- Amgen Lays Off 69 Local Employees
- Researcher, Physician Plead Guilty to Federal Fraud Charges
- Quintiles Announces Acquisitions
- Baxter 3rd-Quarter Profit Rises 10 Percent
- Amgen Laying Off About 380 in R&D
- Eli Lilly Reports Decline in Q3 Net Profit
- Marketing, Severance Costs Cut Lilly's 3rd-Quarter Profits 6 Percent
- Greene LLP Announces $14.5 Million Settlement with Pfizer, Inc. in False Claims Act Case Alleging Off-Label Promotion of Detrol
October 21, 2011
- FDA Drug Safety Communication: Updated Information about the Drug Interaction between Linezolid (Zyvox) and Serotonergic Psychiatric Medications
- FDA Drug Safety Communication: Updated Information about the Drug Interaction between Methylene Blue (methylthioninium chloride) and Serotonergic Psychiatric Medications
- Biogen Says Potential MS Drug Outperforms Placebo
- Patheon Lands $18M Contract
- Biotech Company IRX Moves From NY to FL
- WSJ Reports Investigation Into SAC Capital
- Allos Therapeutics Announces Termination of Merger Agreement with AMAG Pharmaceuticals
- Biotie Informed That Merck Serono Is Returning Full Global Rights for Safinamide to Newron
- MSD and Economic Development Board Sign Long-Term Agreement for Significant New Investments in Singapore
- Abbott CEO Miles White Chooses Longtime No. 2, Friend Richard Gonzalez to Head Spinoff Company
October 24, 2011
- Questions Loom over Status of Shuttered McNeil Plant
- FDA Communication on Use of Jet Injectors with Influenza Vaccines
- Ironwood and Forest Announce Linaclotide New Drug Application for the Treatment of Irritable Bowel Syndrome with Constipation and Chronic Constipation Accepted for FDA Review
- Astellas Launches First TV Commercial
- Cubist Pharmaceuticals to Acquire Adolor
- AG Gansler Reaches Medicaid Fraud Settlement with Pfizer
- Merck Serono Launches easypod Connect in Europe
- Bayer Expects to Start Leaving Wayne in 2013
- FDA Advises Against Flu Shots Given by Jet Injectors
- Pfizer to Pay $14m to Settle Allegations of Illegal Off-Label Marketing of Urology Drug Detrol
- Attorney General's Office Reaches Settlement with Pfizer, Inc. - Company to Pay State $102,000
- FDA Approves First Generic Olanzapine to Treat Schizophrenia, Bipolar Disorder
October 25, 2011
- Novartis 3Q Profit Up 7 Pct; Plans 2,000 Jobs Cuts
- Abbott Labs Says FDA Clears Leukemia Test
- Momenta: Generic Lovenox Will Be Launched in 4Q
- Pop Test Cortisol acquires chemotherapy sensitizer Org34517 from Merck & Co.
- Acton Pharmaceuticals, Inc. Announces License Agreement with Sanofi U.S. for NASACORT HFA? (triamcinolone acetonide) Nasal Aerosol
- Lilly Announces Withdrawal of Xigris Following Recent Clinical Trial Results
- Roche Madison Sold to Arrowhead Research
- Sanofi Appoints David Meeker Chief Executive Officer of Genzyme
- National Prescription Drug Take Back Day, October 29, 2011
October 26, 2011
- Flu Shots Not as Effective as Believed, New Study Shows
- Bristol-Myers Squibb and Gilead Sciences Announce Licensing Agreement for Development and Commercialization of New Fixed-Dose Combination Pill for People Living with HIV
- Study: R&D Spending Up
- Advisers Say Boys Should Get HPV Vaccine
- Phase III Trial of Bayer's Investigational Compound Regorafenib (BAY 73-4506) in Metastatic Colorectal Cancer Meets Primary Endpoint of Improving Overall Survival
- GSK Delivers Strong Q3 Performance With Underlying Sales Growth of 6% and Reported Sales Growth of 3%
- CMC Biologics Announces Agreement With Daiichi Sankyo Company to Develop and Manufacture Antibodies
- CDC Advisory Committee on Immunization Practices Votes for Expanded Use of Gardasil in Boys and Young Men
- Q3/2011: Merck Total Revenues Increase by 4% to ? 2.5 Billion
- Merck Kgaa Net Rises 7.5 Percent to $315 Million
- GlaxoSmithKline Q3 Net Profit Up 7 Percent
- Conatus Pharmaceuticals Terminates Phase 2 Clinical Trial of CTS-1027
- Quintiles Agrees to Acquire Premier GLP Bioanalytics Laboratory, Creating Full-Spectrum Lab Solution for Drug Development
October 27, 2011
- Scarcity of Drugs Alarms Doctors
- Bristol-Myers Squibb Delivers Strong Third Quarter with Important Clinical Data, Solid Operating Results and Continued Focus on Business Development
- Boston Scientific Introduces First iPad App for Physicians to Educate Patients About Cardiovascular Diseases and Treatments
- Pfizer Establishes Precision Medicine Research Collaboration With Medco
- Mylan's Third Quarter 2011 Adjusted Diluted EPS Increases 28% to $0.55
- After A Good Third Quarter: Bayer Confirms Group Outlook
- Biogen Idec and Portola Pharmaceuticals Announce Global Collaboration for Oral Syk Inhibitor Program Targeting Autoimmune and Inflammatory Diseases
- Bristol-Myers 3Q Profit Rises 2 Pct. As Sales Jump
- Bayer 3rd-Quarter Earnings More Than Double
- AstraZeneca Q3 Net Profit Boosted By Disposal
- Pfizer Pneumonia Vaccine Gets Wider EU Approval
- Quintiles to Acquire Advion BioServices
October 28, 2011
- FDA Drug Safety Communication: Updated Information about the FDA-funded Study on Risk of Blood Clots in Women Taking Birth Control Pills Containing Drospirenone
- Merck Announces Third Quarter 2011 Financial Results
- Biogen Idec Reports Third Quarter 2011 Results
- Shire plc: Continued Strong Product Sales Performance in Q3: On Track to Deliver Significant 2011 Earnings Growth
- Gilead Sciences Announces Third Quarter 2011 Financial Results
- United Therapeutics Says 3Q Profit Doubles
- Spring-Ford to Reimburse Glaxo $6.5 Million in Taxes
- Study Confirms Some Contraceptive Pills More Likely to Cause Blood Clots
- Merck 3Q Profit Soars, Beats Analysts' Views
- Aspirin Cuts Cancer Rates in People with Hereditary Risk by More than Half
- Newron Is Exploring All Options for Safinamide
October 31, 2011
- Daiichi Sankyo: Announcement of Financial Results for the 2Q of Fiscal 2011
- Pfizer Completes Acquisition of Icagen
- Astellas Revises Consolidated Business Forecasts for the First Six Months of Fiscal Year 2011 Ending March 31, 2012
- Obama to Order Agency to Help Reduce Drug Shortage
- Repligen Acquires Business of Novozymes Biopharma Sweden AB
- Watson Confirms Court Grants Preliminary Injunction Preventing Launch of Generic Lovenox
- Monthly Roundup - October 2011
